Airwheel Extends Smart Rideable Carry-On Hand Scooter Ai Wheel Robot 20inch Cabin Luxury Suitcase Momentum at the 140th Canton Fair 
MicroVision Begins Commercial Production of MOVIA(TM) Pro for Superior Short-Range Sensing and Onboard Perception, Enabling Physical AI at the Edge 
ASN 2026: HighTide Therapeutics Presents New HTD1801 Data Highlighting Therapeutic Potential in Chronic Kidney Disease 
New Global Initiative Seeks to Modernize Health Workforce Mobility 
P&G, Nestle, Mars, AstraZeneca, ITC and Bekaert win OMP Supply Chain Awards PharmAla Ships MDMA to Mind Medicine Australia and Orygen Institute
PharmAla Continues to Support Clinical Trials as the Foremost Supplier of GMP LaNeo MDMA in…
PharmAla Ships MDMA to Mind Medicine Australia and Orygen Institute
PharmAla Continues to Support Clinical Trials as the Foremost Supplier of GMP LaNeo MDMA in…
Arcutis and Huadong Announce Strategic Collaboration and Licensing Agreement for Topical Roflumilast in Greater China and Southeast Asia
Arcutis to receive $30 million upfront payment and is eligible to receive potential development and…
Arcutis and Huadong Announce Strategic Collaboration and Licensing Agreement for Topical Roflumilast in Greater China and Southeast Asia
Arcutis to receive $30 million upfront payment and is eligible to receive potential development and…
Third Harmonic Bio Announces Second Quarter 2023 Financial Results
Introduced next-generation oral KIT inhibitor product candidate THB335, which retains the potency and selectivity of…
Third Harmonic Bio Announces Second Quarter 2023 Financial Results
Introduced next-generation oral KIT inhibitor product candidate THB335, which retains the potency and selectivity of…
Molecular Templates, Inc. Reports Second Quarter 2023 Financial Results and Business Update
AUSTIN, Texas, Aug. 10, 2023 (GLOBE NEWSWIRE) — Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or…
Molecular Templates, Inc. Reports Second Quarter 2023 Financial Results and Business Update
AUSTIN, Texas, Aug. 10, 2023 (GLOBE NEWSWIRE) — Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or…
Phathom Pharmaceuticals Reports Second Quarter 2023 Results
Prior Approval Supplement (PAS) for VOQUEZNA® TRIPLE PAK® and VOQUEZNA® DUAL PAK® assigned a Prescription…
Phathom Pharmaceuticals Reports Second Quarter 2023 Results
Prior Approval Supplement (PAS) for VOQUEZNA® TRIPLE PAK® and VOQUEZNA® DUAL PAK® assigned a Prescription…
Vaxxinity Announces Publication of UB-311 Safety, Tolerability, Immunogenicity, and Clinical Efficacy Data from Phase 2a Trial in Alzheimer’s Disease
Phase 2a data published in The Lancet’s eBioMedicine supports further development of UB-311 The paper…
Vaxxinity Announces Publication of UB-311 Safety, Tolerability, Immunogenicity, and Clinical Efficacy Data from Phase 2a Trial in Alzheimer’s Disease
Phase 2a data published in The Lancet’s eBioMedicine supports further development of UB-311 The paper…
Candel Therapeutics Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights
NEEDHAM, Mass., Aug. 10, 2023 (GLOBE NEWSWIRE) — Candel Therapeutics, Inc. (Candel or the Company)…
Candel Therapeutics Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights
NEEDHAM, Mass., Aug. 10, 2023 (GLOBE NEWSWIRE) — Candel Therapeutics, Inc. (Candel or the Company)…
Ikena Oncology Reports Second Quarter 2023 Financial Results and Corporate Update
Initial clinical data for IK-930 monotherapy dose escalation expected in the fourth quarter 2023 IK-595,…
Ikena Oncology Reports Second Quarter 2023 Financial Results and Corporate Update
Initial clinical data for IK-930 monotherapy dose escalation expected in the fourth quarter 2023 IK-595,…
IMUNON Reports Second Quarter 2023 Financial Results and Provides Business Update
Advances Non-Viral DNA-Mediated Immunotherapy and Next-Generation Vaccine Programs with Multiple Near-Term Milestones Supported by a…
IMUNON Reports Second Quarter 2023 Financial Results and Provides Business Update
Advances Non-Viral DNA-Mediated Immunotherapy and Next-Generation Vaccine Programs with Multiple Near-Term Milestones Supported by a…
Artelo Biosciences Reports Second Quarter 2023 Financial Results and Provides Business Update
$14.0 Million in Cash and Investments as of June 30, 2023; Cash Runway Expected to…
Artelo Biosciences Reports Second Quarter 2023 Financial Results and Provides Business Update
$14.0 Million in Cash and Investments as of June 30, 2023; Cash Runway Expected to…